secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2025-03-17T23:59:59+00:00
Accession:  0000950170-25-040248
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen gets Nasdaq delisting notice; appeals; reports Q4 loss of $8.7M, China sale to AstraZeneca
--------------------------------------------------------------------------------

- Nasdaq notified FibroGen on March 12, 2025 that it failed to regain $1.00 minimum bid price; delisting stayed after March 14 appeal; hearing pending.
- Q4 2024 revenue from continuing ops $3.1M (vs $3.6M Q4 2023); net loss $8.7M ($0.08 loss per share) vs $62.5M ($0.63) prior year.
- Full year 2024 net loss from continuing ops $153.1M ($1.53 loss/share) vs $323.0M ($3.32) in 2023; total cash $121.1M at year-end.
- Announced sale of FibroGen China to AstraZeneca for ~$160M; expected close by mid-2025; proceeds to repay term loan, extend cash runway into 2027.
- Upcoming milestones: Phase 2 monotherapy trial of FG-3246 in mCRPC start by mid-2025; topline combo study results 2H 2025; FDA meeting for roxadustat in LR-MDS in Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017025040248/0000950170-25-040248-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017025040248/fgen-20250312.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-040248

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer